Status:
SUSPENDED
Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder
Lead Sponsor:
Guangzhou Women and Children's Medical Center
Conditions:
Autism Spectrum Disorder
Eligibility:
All Genders
2-15 years
Phase:
PHASE2
Brief Summary
Autism spectrum disorder (ASD) is a life-long neurodevelopmental disorder characterized by qualitative abnormalities in reciprocal social interactions and patterns of communication, and by a restricte...
Detailed Description
The use of medications in adolescents and young adults with ASD is extremely common. few data address the effectiveness and harms of medications specifically in this population. A previous study repor...
Eligibility Criteria
Inclusion
- meet autism diagnostic criteria based on DSM-5/ADI-R/ADOS
- children aged 2 years through 15 years of age
- parents/guardians can cooperate with the study and sign informed consent
- ASA score I or II
Exclusion
- with epilepsy or other genetic diseases
- changes in drugs or in any intervention during the study
- Presence of cardiac disease including coronary artery disease, congestive heart failure, or uncontrolled hypertension per medical history
- Airway instability, tracheal surgery, or tracheal stenosis per medical history.
- History of drug or alcohol abuse
- Central nervous system masses or hydrocephalus per medical history
Key Trial Info
Start Date :
January 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03434366
Start Date
January 20 2018
End Date
December 30 2023
Last Update
April 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Women and Children Medical Center
Guangzhou, Guangdong, China, 510000